| Study | Location | Study size | Study design | Enrollment period | Fertility treatment | Matched/adjusted factors | Follow-up (years) |
| Ron et al. [10] | Israel | 2,575 | Retrospective cohort study | 1964–1974 | Unknown | Unknown | 12.3 |
| Althuis et al. [11] | USA | 8,422 | Retrospective cohort study | 1965–1988 | Clomiphene, gonadotropins | Study site, age at follow-up, calendar year of follow-up, gravidity at entry, parity at follow-up | 18.8 |
| Hannibal et al. [12] | Denmark | 54,362 | Case-cohort study | 1963–1998 | Clomiphene, gonadotropins, progesteronr, hCG, GnRH | Age at first live birth, parity status | 8.8 |
| Calderon-Margalit et al. [13] | Israel | 15,030 | Retrospective cohort study | 1974–1976 | Clomiphene, gonadotropins, other unknown fertility drugs | Age at first birth, geographic origin, social class, education, parity, time to conception, mean body mass index | 29 |
| Yli-Kuha et al. [14] | Finland | 18,350 | cohort study | 1996–1998 | IVF | Age, marital status, socioeconomic position | 7.8 |
| Reigstad et al. [17] | Norway | 806,248 | Retrospective cohort study | 1984–2010 | IVF, ICSI, others | Age at start follow-up, parity at entry, method of ART, duration of follow-up | 7.3 |
| Brinton et al. [18] | USA | 9,892 | Retrospective cohort study | 1965–1988 | Clomiphene, gonadotropins, combination | Race, reproductive status at first clinic visit, reproductive status at follow-up, number of births at follow-up, age at first birth, age at menarche, BMI at first clinic visit, ever smoke, cause of infertility | 30 |
| Reigstad et al. [19] | Norway | 1,353,724 | Retrospective cohort study | 1960–1996 | Clomiphene citrate, GnRH, gonadotropins, hCG | Birth year, parity, CC exposure, region of present residence, number of children at entry, age at start of follow-up, age at first cancer, types of treatment, number of cycles of ART, dose of clomiphene citrate | 18 |
|
|